Risk factors for Clostridium difficile infection in hemato-oncological patients: A case control study in 144 patients

Evidence on risk factors for Clostridium difficile infection (CDI) in hemato-oncologic patients is conflicting. We studied risk factors for CDI in a large, well-characterized cohort of hemato-oncological patients. 144 hemato-oncological patients were identified in this retrospective, single center s...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2016-08, Vol.6 (1), p.31498-31498, Article 31498
Main Authors: Fuereder, Thorsten, Koni, Danjel, Gleiss, Andreas, Kundi, Michael, Makristathis, Athanasios, Zielinski, Christoph, Steininger, Christoph
Format: Article
Language:English
Subjects:
692/4028/67
692/699/255/1911
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents - therapeutic use
Case-Control Studies
Clostridium Infections - drug therapy
Clostridium Infections - epidemiology
Cross Infection - microbiology
Diarrhea - microbiology
Drug Therapy
Drug Therapy, Combination
Female
Hematologic Neoplasms - complications
Hematologic Neoplasms - drug therapy
Hematologic Neoplasms - microbiology
Humanities and Social Sciences
Humans
Male
Middle Aged
multidisciplinary
Retrospective Studies
Risk Factors
Science
Science (multidisciplinary)
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Evidence on risk factors for Clostridium difficile infection (CDI) in hemato-oncologic patients is conflicting. We studied risk factors for CDI in a large, well-characterized cohort of hemato-oncological patients. 144 hemato-oncological patients were identified in this retrospective, single center study with a microbiologically confirmed CDI-associated diarrhea. Patients were compared with 144 age and sex matched hemato-oncologic patients with CDI negative diarrhea. Risk factors such as prior antimicrobial therapy, type of disease, chemotherapy and survival were evaluated. CDI-positive patients received more frequently any antimicrobial agent and antimicrobial combination therapy than CDI-negative patients (79% vs. 67%; OR = 2.26, p = 0.038 and OR = 2.62, p = 0.003, respectively). CDI positive patients were treated more frequently with antimicrobial agents active against C. difficile than CDI negative ones (25% vs. 13%; OR = 2.2, p = 0.039). The interval between last chemotherapy and onset of diarrhea was significantly shorter in patients without CDI (median, 17 days vs 36 days; p 
ISSN:2045-2322
2045-2322
DOI:10.1038/srep31498